Literature DB >> 7548714

Design and analysis of group sequential logrank tests in maximum duration versus information trials.

K Kim1, H Boucher, A A Tsiatis.   

Abstract

When monitoring a clinical trial with failure time data using the logrank test and the type I error spending function approach, the information time has to be estimated as a fraction of the maximum number of failures. In maximum duration trials, the denominator of this fraction is a random quantity and has to be estimated; besides, there are two candidates for the denominator, one under the null hypothesis of no treatment difference and the other under the specified alternative hypothesis. Either way, some adjustments are necessary in determining group sequential boundaries in order to maintain type I error at a desired significance level. As a consequence, the type I error spending function will be altered from the one chosen for the design, thus affecting the operating characteristics of the subsequent group sequential logrank tests. In maximum information trials, however, the maximum amount of information is fixed, and thus the estimate of the information time is always unbiased. The net effect is that computation of group sequential boundaries becomes straightforward, with a potential saving in study durations as compared to maximum duration trials. We will illustrate how adjustments are made in maximum duration trials to maintain type I error when the information times are estimated with the information horizons under the null and alternative hypotheses and present numerical explorations to compare robustness of two different estimates of the information times. We then propose a design procedure for maximum information trials and investigate the properties of maximum information trials for different group sequential boundaries. We also compare maximum information trials and maximum duration trials based on an example.

Mesh:

Year:  1995        PMID: 7548714

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  2 in total

1.  Information fraction estimation based on the number of events within the standard treatment regimen.

Authors:  Ha M Dang; Todd Alonzo; Meredith Franklin; Wendy J Mack; Mark D Krailo; Sandrah P Eckel
Journal:  Biom J       Date:  2020-07-06       Impact factor: 2.207

2.  Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order.

Authors:  Ruben P A van Eijk; Stavros Nikolakopoulos; Kit C B Roes; Lindsay Kendall; Steve S Han; Arseniy Lavrov; Noam Epstein; Tessa Kliest; Adriaan D de Jongh; Henk-Jan Westeneng; Ammar Al-Chalabi; Philip Van Damme; Orla Hardiman; Pamela J Shaw; Christopher J McDermott; Marinus J C Eijkemans; Leonard H van den Berg
Journal:  Neurology       Date:  2021-07-27       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.